Xtandi, Astellas’ roughly $6 billion prostate cancer juggernaut by annual sales, is set to lose U.S. patent protection in ...

The FDA has told the makers of six flu vaccines that they need to add a notification to the label of their shots, warning of ...

This time, Tecvayli excelled as a solo agent, reducing the risk of disease progression or death by 71% over standard of care ...

Hologic has drafted professional basketball player Erica Wheeler to raise awareness of cervical cancer screening, putting the ...

The regulator’s Office of Prescription Drug Promotion (OPDP) has already sent out two letters alleging “false or misleading” ...

The move comes in response to increasing delivery demands for GLP-1s, plus broader conversations about pharmaceutical ...

The past year was one of turbulence and change at Novo Nordisk, and, while the Danish drugmaker still has its work cut out ...

In fact, the price of such vouchers has been climbing steadily in recent months, according to public disclosures surrounding ...

As part of its mission to make a dent in the sizable presbyopia market, Lenz Therapeutics has scoped out a star-studded ...

After a flurry of Big Pharma deals in the first week of the new year, the life sciences industry is heading to San Francisco ...

After a whirlwind of conference news Monday, we're doing it all over again with Day 2 of the J.P. Morgan Healthcare ...

Though far from the first large drugmaker to strike a pricing deal with the Trump administration, AbbVie’s new accord is ...